DAX22.922 -1,1%Est505.633 -1,1%MSCI World4.343 -0,1%Top 10 Crypto8,7400 +0,8%Nas21.888 -0,5%Bitcoin59.367 -0,5%Euro1,1574 +0,3%Öl109,6 -0,1%Gold4.672 +0,5%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 Lufthansa 823212 NVIDIA 918422 Siemens Energy ENER6Y SAP 716460 Deutsche Telekom 555750 BASF BASF11 Plug Power A1JA81 Allianz 840400 Microsoft 870747 Mercedes-Benz Group (ex Daimler) 710000 Tesla A1CX3T DroneShield A2DMAA Novo Nordisk A3EU6F RENK RENK73
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Trumps Ultimatum läuft ab: DAX schließt tiefrot -- Siemens Energy und AWS treiben Partnerschaft voran -- D-Wave, Commerzbank, Ölaktien, Rüstungsaktien, Plug Power, Almonty, BYD, Nike im Fokus
Top News
Cardano: So viel Verlust hätte eine Investition von vor 1 Jahr bedeutet Cardano: So viel Verlust hätte eine Investition von vor 1 Jahr bedeutet
Wie viel Verlust eine Stellar-Investition von vor 1 Jahr eingebracht hätte Wie viel Verlust eine Stellar-Investition von vor 1 Jahr eingebracht hätte
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Syndax Pharmaceuticals Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
21,05 EUR -0,55 EUR -2,55 %
STU
20,61 EUR -1,19 EUR -5,46 %
HAML
finanzen.net zero
Syndax Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.1,92 Mrd. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2AFL6

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS87164F1057

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolSNDX

Syndax Pharmaceuticals Aktien News

DatumMeistgelesen
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Announces Participation in February Investor Conferences
PR NewswireIncyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
Wer­bungSyndax Pharmaceuticals-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireSyndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
PR NewswireSyndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) for Potential Breaches of Fiduciary Duty By Its Board of Directors
PR NewswireSyndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial
PR NewswireSyndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Announces Participation at the Citi 2024 Global Healthcare Conference
PR NewswireSyndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
PR NewswireSyndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib
PR NewswireSyndax Reports Third Quarter 2024 Financial Results and Provides Business Update
PR NewswireSyndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024
PR NewswireSyndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting
PR NewswireSyndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting
PR NewswireSyndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Announces Participation in November Investor Conferences
PR NewswireSyndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update
PR NewswireSyndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia
PR NewswireSyndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress
PR NewswireSyndax Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC
PR NewswireSyndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare Conference
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors
PR NewswireSyndax Announces Participation at the Bank of America Securities 2024 Health Care Conference
PR NewswireSyndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
PR NewswireSyndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
PR NewswireSyndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session

Syndax Pharmaceuticals News

Syndax Pharmaceuticals News: auf dieser Seite finden Sie alle Syndax Pharmaceuticals News und Nachrichten zur Syndax Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Syndax Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Syndax Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.